07:00 , Mar 30, 2015 |  BioCentury  |  Finance

Poland backing innovators

The Polish government is backing the country's first life sciences VC to help build innovative life science companies in a country known for its services-oriented healthcare sector. While the capital and infrastructure are available, one...
07:00 , Jun 3, 2013 |  BioCentury  |  Finance

Seeds to trees

Flush with cash from its existing holdings and not seeing enough worthwhile venture deals to spend it on, Novo A/S has decided to expand its growth equity investments in mature companies. After a proof-of-principle deal...
07:00 , May 27, 2013 |  BC Week In Review  |  Company News

Xellia Pharmaceuticals A/S, Novo A/S deal

*** Xellia Pharmaceuticals A/S, Oslo, Norway   Novo A/S, Hellerup, Denmark   Business: Infectious   Novo will acquire infectious disease company Xellia from private equity firm 3i Group and other shareholders for about $700 million. In 2008, 3i...
00:01 , May 22, 2013 |  BC Extra  |  Company News

Novo A/S acquires Xellia

Novo A/S (Hellerup, Denmark) will acquire infectious disease company Xellia Pharmaceuticals A/S (Oslo, Norway) from private equity firm 3i Group for about $700 million. In 2008, 3i acquired Xellia, which develops and manufactures active pharmaceutical...
08:00 , Nov 8, 2010 |  BC Week In Review  |  Company News

OctoPlus management update

OctoPlus N.V. (Euronext:OCTO), Leiden, the Netherlands   Business: Drug delivery   Departing: CEO Simon Sturge, effective Jan. 1, 2011; the company's board nominated Jan Egberts, formerly senior advisor in healthcare investments for 3i Group and CEO of...
00:26 , Nov 5, 2010 |  BC Extra  |  Company News

OctoPlus CEO Sturge leaving

Drug delivery company OctoPlus N.V. (Euronext:OCTO) said CEO Simon Sturge will depart on Jan. 1, 2011, to lead a division of an undisclosed pharmaceutical company. The company's board nominated Jan Egberts for appointment as CEO...
07:00 , Mar 24, 2008 |  BioCentury  |  Finance

Nomura's investments

Nomura's investments Nomura's investments Nomura Phase4 Ventures has invested in at least 25 biotechs since 1999. Usually Nomura's contribution for an initial investment will be some $15-$25 million of the round, although in subsequent rounds...
08:00 , Feb 11, 2008 |  BC Week In Review  |  Company News

Alpharma, 3i Group plc deal

Private equity firm 3i will acquire Alpharma's active pharmaceutical ingredients manufacturing unit for about $395 million in cash. The unit, which specializes in fermented antibiotics, had sales of $138.7 million for the nine months ended...
00:42 , Oct 6, 2006 |  BC Extra  |  Financial News

Santhera raises EUR 10 million

Musculoskeletal and endocrine company Santhera (Liestal, Switzerland) raised EUR 10 million ($12.7 million) in a series C round led by NGN Capital. New investors NeoMed Management; Schroder Investment Management; and BioMedinvest were joined by existing...
07:00 , Aug 28, 2006 |  BC Week In Review  |  Company News

MerLion board of directors update

MerLion Pharmaceuticals Pte. Ltd., Singapore   Business: High throughput screening   Appointed: Clemens Doppler, a director at 3i Group Investment LP   ...